Related by context. All words. (Click for frequent words.) 65 serum magnesium 63 mmol l 61 sUA 61 8mg/kg 61 Hb A1C 61 intact parathyroid hormone 61 serum urate 60 alanine aminotransferase 60 serum creatinine levels 60 SGPT 60 aminotransferases 60 μmol L 59 mL/min/#.# m 2 59 μg kg 59 Hb levels 59 aspartate aminotransferase AST 59 hypomagnesemia 59 #.#mmol L [002] 59 urinary cortisol 59 transferrin saturation 59 transaminase elevations 59 mcg mL 59 plasma leptin 59 oral antidiabetic medication 59 alanine aminotransferase ALT 59 #.#mg/dL 58 ALT elevations 58 aspartate aminotransferase 58 baseline serum creatinine 58 4mg/kg 58 corticosteroid dose 58 kilogram mg kg 58 nmol liter 58 mg/m2/day 58 μg liter 58 g dl 58 serum CRP 58 anemia hemoglobin 58 % Confidence Interval 58 glycosylated hemoglobin HbA1c 58 glutamyl 58 x ULN 58 μg L 58 serum uric acid 58 pg mL 58 serum phosphate 58 apolipoprotein B 58 Cmax 58 leukopenia 58 abacavir lamivudine 58 moderate renal impairment 58 lactate dehydrogenase LDH 58 mIU L 58 benazepril 58 serum potassium 58 arterial thromboembolic events 58 pg ml 58 lispro 58 iPTH 57 serum phosphate levels 57 serum urate levels 57 mEq L 57 SCr 57 hyperphenylalaninemia HPA due 57 serum ALT 57 -#.# mg dL [002] 57 glycated hemoglobin levels 57 3mg/kg 57 plasma folate 57 lopinavir r 57 CCyR 57 autoantibody positive 57 mcg BID 57 thyrotropin 57 CK MB 57 DAS# remission 57 PSA nadir 57 serum homocysteine 57 leukocyte count 57 certolizumab 57 adrenocorticotropic hormone 57 NPH insulin 57 pmol L 57 #-#,# mg 57 Mg Uk 57 CK # plasma concentrations 57 #ng/ml 57 acarbose 57 A1c levels 57 HBeAg seroconversion 57 neutrophil counts 57 glulisine 57 serum retinol 57 BENICAR HCT 57 ALT elevation 57 prednisone prednisolone 57 microg 57 antiarrhythmic drug 57 plus prednisone prednisolone 57 #mmHg [001] 57 NovoLog ® Mix 57 adjunctive ABILIFY 57 bioavailable testosterone 57 HOMA IR 57 lipid elevations 57 serum HBV DNA 57 reduce serum phosphate 57 NOAEL 56 oxycodone IR 56 thromboxane A2 56 albumin excretion 56 serum PTH 56 MIC# [001] 56 plasma HCV RNA 56 T2DM 56 ULTRAM ER 56 hemoglobin A1c HbA1c 56 dermatologic toxicities 56 linear pharmacokinetics 56 methylmalonic acid 56 hematopoietic cancers 56 achieved ACR# 56 lumbar spine BMD 56 #mm Hg 56 adjunctive placebo 56 Peg IFN 56 atorvastatin #mg 56 hepatorenal syndrome 56 hypercalcemia 56 Pharmacokinetic parameters 56 serum TSH 56 #mg/day [002] 56 concentration Cmax 56 urine albumin 56 nmol 56 hemoglobin Hb 56 daunorubicin 56 epoetin 56 baseline LDH 56 serum aminotransferase levels 56 β blockers 56 naïve HCV 56 ug ml 56 artery stenosis 56 serum phosphorus levels 56 umol L 56 somatostatin analog 56 relapsed MM 56 Pegylated Interferon 56 elevated transaminases 56 macroalbuminuria 56 generalized edema 56 dose pravastatin 56 beclomethasone dipropionate 56 lactate dehydrogenase 56 primary aldosteronism 56 creatinine ratio 56 #mg/m# [001] 56 ng dL 56 CrCl 56 μg mL 56 serum testosterone 56 corrected QT interval 56 ml kg 56 hyperphosphatemia elevated serum phosphorous 56 elevated ALT 56 Peginterferon Alfa 2a 55 oral prednisolone 55 ritonavir boosted 55 ULORIC 55 antiplatelet medications 55 #OHD 55 detemir 55 mg ustekinumab 55 thyrotropin levels 55 myopathy rhabdomyolysis 55 nitrotyrosine 55 creatinine clearance 55 mmol liter 55 haematologic 55 lamivudine refractory patients 55 #.#/#.# mmHg [001] 55 μg d 55 severe renal impairment 55 titrated glipizide 55 chloride secretion 55 FBPase 55 troponin T 55 tolterodine ER 55 QTcF 55 elevated LDL cholesterol 55 nanomolar 55 PASI scores 55 aspirin clopidogrel 55 #mg/dL [002] 55 #mg BID [003] 55 glomerular filtration rate 55 HIV HCV coinfected 55 octreotide LAR 55 severe neutropenia 55 #mg/dL [001] 55 hepatic insufficiency 55 aminotransferase levels 55 chlorambucil 55 KDOQI 55 triiodothyronine 55 irbesartan 55 gastric pH 55 hypophosphatemia 55 nonnucleoside reverse transcriptase inhibitors 55 tipranavir r 55 refractory NSCLC 55 #mg/dl 55 bezafibrate 55 mg tid 55 mm ³ 55 HbA1C 55 sulfonylurea metformin 55 asymptomatic carotid stenosis 55 IOP lowering 55 abdominal adiposity 55 baseline HbA1c 55 sUA levels 55 cGy 55 metastatic GIST 55 fluticasone propionate FP 55 receiving APTIVUS r 55 FOSRENOL ® 55 CR nPR 55 sulphonylurea 55 Myoglobin 55 PaO 2 55 pegylated interferons 55 piperacillin tazobactam 55 HES CEL 55 colorectal adenoma 55 mg m² 55 TNF antagonist 55 rizatriptan 55 LEXIVA r 55 per deciliter mg 55 leucopenia 55 ARCOXIA 55 salmeterol fluticasone propionate 55 albumin excretion rate 55 protein excretion 54 deoxy 54 uM 54 IFN α 54 #mmHg [002] 54 fasting plasma glucose FPG 54 estramustine 54 creatine kinase MB 54 #/#mmHg 54 serum sodium 54 morphometric vertebral fractures 54 intratumoral 54 hematologic toxicity 54 symptomatic intracranial hemorrhage 54 baseline A1C 54 maximally tolerated dose 54 Pemetrexed 54 achieved statistical significance 54 serum potassium levels 54 indinavir 54 5-FU/LV 54 parasitaemia 54 ertapenem 54 thyroglobulin 54 IU ml 54 mIU ml 54 SSc 54 q8h 54 mmHg diastolic 54 folate concentrations 54 Retreatment 54 normal ULN 54 imiquimod cream 54 isoenzyme 54 plasma uric acid 54 subcutaneous dose 54 highly emetogenic 54 mitoxantrone plus 54 transaminases 54 X ULN 54 FOLFOX regimen 54 Hcy 54 mU liter 54 tirofiban 54 CVD mortality 54 serum transaminases 54 -#.# mg dL [001] 54 biologic DMARD 54 mg simvastatin 54 fosamprenavir 54 elevated LDH 54 leukotriene receptor antagonists 54 supine hypertension 54 transdermal estradiol 54 #OHD levels 54 lymphopenia 54 dalteparin 54 log# reduction 54 oxycodone CR 54 interferon alfa 2b 54 undetectable viral 54 ergocalciferol 54 VELCADE melphalan 54 haematological toxicity 54 ACh 54 mcg kg 54 nmol L. 54 unconjugated 54 neurodevelopmental impairment 54 sensory neuropathy 54 eosinophil count 54 RfD 54 Paraplatin ® 54 doxorubicin cyclophosphamide 54 Arch Intern Med 54 polymyxin B 54 % CI #.#-#.# [001] 54 Nilotinib 54 CIN3 54 IV bisphosphonates 54 FOLFIRI alone 54 PREZISTA r 54 diabetes mellitus DM 54 ACR# responses 54 ceftriaxone 54 XEPLION R 54 LV dysfunction 54 biochemical relapse 54 serum calcium levels 54 lymphoid blast 54 RLAI 54 mm Hg systolic 54 azilsartan medoxomil 54 MADRS score 54 nmol L 54 #mg #mg #mg [003] 54 PSADT 54 lanthanum carbonate 54 #mg BID [001] 53 Adjuvant chemotherapy 53 plus COPEGUS 53 ug mL 53 elevated triglyceride levels 53 mRCC 53 dapagliflozin plus 53 REYATAZ r arm 53 mIU mL 53 xanthine oxidase inhibitor 53 saline placebo 53 mg BID dose 53 ribavirin therapy 53 Peginterferon 53 complete cytogenetic response 53 confidence interval #.#-#.# 53 μg ml 53 laropiprant 53 HbF 53 urinary excretion 53 rapid virological response 53 ug kg 53 CR CRu 53 DAS# scores 53 mL/min/#.# m2 53 interleukin IL -6 53 Platinol ® cisplatin 53 INVEGA ® 53 hepatic enzymes 53 TAXUS p value 53 AUC0 53 Eur J Endocrinol 53 antibody titer 53 ANCA associated 53 heavily pretreated 53 infliximab monotherapy 53 Fasting glucose 53 micromoles 53 SpO 2 53 EGFR TKI 53 statistical significance p 53 mg QD 53 +# pips #,# 53 nonfasting triglycerides 53 K DOQI 53 liver histology 53 neutropenia dehydration dyspnea 53 HbA1C levels 53 maximal dose 53 TRAIL R1 53 histologic subtype 53 β blocker 53 elevated fasting glucose 53 diastolic hypertension 53 inecalcitol 53 Palm olein Mal 53 FluCAM 53 epoetin alfa 53 left ventricular diastolic 53 vincristine doxorubicin 53 seroprotection 53 antidiabetic drugs 53 serum phosphorus 53 pegIFN 53 plus dexamethasone 53 lowest tertile 53 FUSILEV enhances 53 gemcitabine cisplatin 53 daily subcutaneous injections 53 paroxetine sertraline 53 humanized interleukin 6 53 mg qd 53 Flu Cy 53 achieved CCyR 53 isoprostane 53 Doxil ® 53 APTIVUS r 53 recurrent glioblastoma multiforme 53 dexamethasone Decadron 53 Prognostic significance 53 diastolic blood pressures 53 Erythropoietic therapies may 53 adenoma recurrence 53 5 Fluorouracil 53 Aptivus ® 53 urinary albumin excretion 53 ng ml 53 #Gy 53 pyrazinamide 53 baseline FEV 53 achieved PASI 53 thienopyridine 53 dosing frequency 53 ^ sup -1 53 p = #.# [003] 53 avosentan 53 ibandronate 53 Danazol 53 Tysabri infusions 53 ACR# response 53 See CONTRAINDICATIONS 53 ^ sup #m 53 pmol liter 53 amprenavir 53 HbA 1c levels 53 See WARNINGS 53 chronic HCV infection 53 PegIFN 53 pCR 53 lopinavir r arm 53 liver enzymes ALT 52 homocysteine concentrations 52 poor metabolizers 52 virological response 52 CsA 52 GH deficiency 52 preterm neonates 52 FDG uptake 52 #mg/day [001] 52 SUSTENNA TM 52 mean serum phosphorus 52 -#.# log# copies mL 52 metastatic malignant 52 mg p = 52 autoantibody levels 52 multivariable adjusted 52 annualized relapse 52 non splenectomized 52 deferoxamine 52 systemic embolism 52 mmHg systolic 52 deep venous thromboses 52 baseline Hb 52 nmol l 52 #ug [001] 52 peginterferon alfa 2b 52 transgene expression 52 left ventricular hypertrophy 52 inflammatory lesions 52 lipase units 52 ovarian carcinoma 52 HBeAg positive 52 HBeAg negative patients 52 nonfasting triglyceride levels 52 ABILIFY Injection 52 mg BID 52 cholestyramine 52 atazanavir ritonavir 52 TIMP 1 52 Decitabine 52 aortic regurgitation 52 ACEIs 52 ARB telmisartan 52 plus aztreonam 52 hematological parameters 52 blood Phe 52 recurrent genital herpes 52 triglyceride concentrations 52 ® lenalidomide 52 Natalizumab 52 plus methotrexate 52 PegIFN RBV 52 pegylated interferon alfa 2a 52 Hazard Ratio HR 52 pulmonary exacerbations 52 CIMZIA TM 52 -8 -9 52 IFN alfa 52 ADCS CGIC 52 Diabetic nephropathy 52 investigational oral inhibitor 52 HBeAg negative 52 mm Hg diastolic 52 Nasacort AQ 52 REMINYL ® 52 mg d 52 serum prostate 52 Thrombotic thromboembolic complications 52 J Am Coll 52 DLTs 52 sitagliptin Januvia 52 adrenocortical 52 atrophic gastritis 52 corneal curvature 52 + PH# 52 gadobutrol 52 mcg albinterferon alfa 2b 52 TURBT 52 -#.# log# 52 cTnT 52 CLL SLL 52 Cutaneous T 52 #mg dose [002] 52 receiving INTRON 52 cells uL 52 Posaconazole 52 attain statistical significance 52 FTE staffing 52 angina myocardial infarction 52 #.#ng/ml 52 labetalol 52 mU L 52 hemoglobin concentration 52 racemic albuterol 52 mg dosed twice 52 PEG IFN 52 K ras mutations 52 nM 52 cranial irradiation 52 μV 52 confidence intervals CIs 52 placebo PBO 52 q#h 52 polyp recurrence 52 detrusor 52 incidence ≥ 52 comorbid anxiety 52 MULTAQ 52 hepatitis C genotype 52 Pfizer Aricept 52 non hematological toxicities 52 response CCyR 52 Zometa hazard 52 alemtuzumab treated 52 chlorthalidone 52 inhibitory concentration 52 investigational saxagliptin 52 left ventricular systolic 52 cefepime 52 timepoints 52 neutropenic patients 52 adriamycin 52 transaminase levels 52 cytidine nucleoside analog 52 mg TID 52 hydroxyvitamin D levels 52 thiazides 52 laboratory abnormalities 52 mcg kg REBETOL 52 tacrolimus ointment 52 hours postdose 52 Cytarabine Liposome Injection 52 splanchnic 52 del 5q MDS 52 hemoglobin concentrations 51 Sumatriptan OS 51 receiving ISENTRESS 51 budesonide pMDI 51 platelet reactivity 51 OADs 51 AST ALT 51 .5 milligrams 51 CD4 + CD# 51 gastric cardia 51 μg dose 51 Y BOCS 51 plasminogen activator inhibitor 51 adrenoceptor 51 Fasting blood glucose 51 J Foot Ankle 51 hepatic fibrosis 51 cells μL 51 Emtriva Viread 51 preoperative PSA 51 clodronate 51 seroprotective 51 mycophenolate mofetil 51 heterozygotes 51 adenosine diphosphate ADP 51 IDDM 51 BARACLUDE ® 51 serum ferritin 51 dasatinib Sprycel ® 51 NATRECOR R 51 RBC folate 51 ZOLINZA 51 Index CDAI 51 #μg [002] 51 nonfatal MI 51 LPV r 51 acitretin 51 microbiologically evaluable 51 pharmacokinetic equivalence 51 neovascular 51 anagrelide 51 paraprotein 51 KRAS mutant tumors 51 cTnI 51 serum triglycerides 51 recurrent venous thromboembolism 51 lymphocytosis 51 apo B 51 undetectable HCV RNA 51 unfavorable cytogenetics 51 experienced virologic failure 51 suppl. 51 DULERA 51 interferon alfa 2a 51 #.#-#.# [005] 51 tissue transglutaminase 51 peginterferon alfa 2a 51 EGFR mutation positive 51 serum triglyceride 51 mitoxantrone 51 glucuronide 51 adjuvant GIST 51 mg kg dose 51 -#.# ± [002] 51 inhibit platelet function 51 % CI #.#-#.# [006] 51 FOLFOX4 51 #.#mmHg 51 â ‰ ¥ 51 aminotransferase 51 CHD mortality 51 dizziness nausea diarrhea 51 Diastolic 51 nevirapine Viramune 51 Secretase 51 nonfatal stroke 51 anthracycline taxane 51 Proc Am Soc 51 hypogonadal 51 administered subcutaneously 51 Upregulation 51 INVEGA ™ 51 CD# CD# 51 QTc 51 mCi m 2 51 Fasting plasma glucose 51 AUCs 51 florbetaben 51 CI -#.# 51 pulmonary exacerbation 51 HER2 expression 51 cyclophosphamide methotrexate 51 mg eq 51 Forodesine HCl 51 mmol L 51 Primary IGFD 51 neurologic progression 51 mg/m2 dose 51 serum albumin 51 highest tertile 51 sustained virological response 51 neurologic impairment 51 antiandrogen 51 evaluating tivozanib 51 Viral load 51 plasma urate 51 LEXIVA 51 hypercalciuria 51 golimumab CNTO 51 plasma glucose concentration 51 CTAP# Capsules 51 CHD CVD 51 receiving prophylactic anticoagulation 51 vitamin D2 51 BPH benign prostatic 51 equimolar 51 Lupuzor ™ 51 ng dl 51 5alpha reductase 51 plasma glucose 51 myelodysplastic myeloproliferative diseases 51 thrombocytosis 51 doxorubicin docetaxel 51 mCi 51 HCV genotype 51 antiandrogens 51 Type IIa 51 reactogenicity 51 recurrent ischemia 51 HBeAg + 51 ribavirin RBV 51 hippocampal atrophy 51 serum folate 51 radiotherapy RT 51 peginterferon alfa 51 serum concentrations 51 intramuscularly 51 myeloproliferative diseases 51 divalproex sodium 51 coronary stenosis 51 abnormal lipid 51 μg dL 51 peak plasma concentrations 51 non squamous NSCLC 51 alfa 2a 51 Stage IIB 51 TT genotype 51 liver transaminases 51 hemodilution 51 % CI #.#-#.# [004] 51 Pegasys plus Copegus 51 paclitaxel carboplatin 51 ATACAND 51 osteopenic 51 diastolic BP 51 neuropathy sensory 51 leukocytosis 51 Hazard Ratio 51 tenofovir emtricitabine 51 #.#mmol L [001] 51 Fas ligand 50 pravastatin Pravachol 50 log# copies mL 50 induced phosphorylation 50 HCV Genotype 50 grade cervical intraepithelial 50 comparator arm 50 XIENCE V PROMUS Stent 50 adiponectin concentrations 50 #ug [002] 50 rebleeding 50 serum testosterone levels 50 doublet chemotherapy 50 nanograms milliliter 50 triglyceride concentration 50 pmol 50 colorectal carcinoma 50 extrapyramidal symptoms EPS 50 AChE inhibitors 50 RNAi therapeutic targeting PCSK9 50 neuritic 50 #,# +# pips #,# [001] 50 Neutropenia 50 bacteriuria 50 Multiple Ascending Dose 50 #mg/kg [002] 50 #.#g/day 50 parkinsonian 50 #.#-#.# [002] 50 oral FTY# 50 castrate resistant prostate cancer 50 azacitidine 50 adverse reactions incidence 50 oxycodone HCl 50 potentially hepatotoxic 50 SUVmax 50 progression TTP 50 carotid IMT 50 Subclinical 50 HER2 amplification 50 nonfatal myocardial infarction 50 mg subcutaneous 50 KRAS mutations occur 50 mg q#h 50 maximally tolerated 50 p = .# [002] 50 mg dl 50 inhibin B 50 regorafenib 50 log# IU mL 50 #.#mg dose 50 endoscopic ultrasonography 50 prostaglandin E 50 pT3 50 CC genotype 50 cells mcL 50 triglyceride lowering 50 Myelosuppression 50 TUNEL 50 ISTODAX 50 Tubulin 50 #mg dose [003] 50 ß carotene 50 % CI #.#-#.# [007] 50 gout flares 50 insulin detemir 50 CI #.#-#.# [001] 50 bortezomib refractory 50 posttreatment 50 #mg/m# [002] 50 hyperhomocysteinemia 50 onset diabetes mellitus 50 HIF 1a 50 mg Lucentis 50 TIMP 50 ng mL 50 PASI score 50 nucleoside analog 50 dosage regimen 50 Capecitabine 50 tipranavir 50 dacarbazine 50 pbb 50 emtricitabine tenofovir 50 bullous 50 hyperplastic 50 Laquinimod 50 tumor xenograft models 50 ouabain 50 antitrypsin 50 balsalazide 50 complement inhibitor eculizumab 50 Alanine 50 = #.#-#.# 50 LDL C 50 serum PSA 50 PLX STROKE targeting 50 ® fluocinonide Cream 50 detectable HCV RNA 50 FOLFOX 50 TNF blocker therapy 50 nucleoside naive 50 acute GvHD 50 Topoisomerase II 50 Pegylated Liposomal Doxorubicin 50 PEGylated anti 50 anthracycline containing 50 linaclotide treated 50 colesevelam HCl 50 TPV r 50 relapsed SCLC 50 unresectable tumors 50 severe periodontitis 50 1beta 50 Novel Inhibitor 50 endothelial activation 50 serotonin norepinephrine reuptake inhibitor 50 CD# expression [001] 50 oral hypoglycemic 50 gemcitabine carboplatin 50 specific lectin receptors 50 leukemia AML 50 carotid stenosis 50 febrile neutropenia 50 metastatic renal cell carcinoma 50 serologically active patients 50 thromboembolic events 50 polypoid 50 cisplatin chemotherapy 50 initiating antiretroviral therapy 50 g dL 50 Herpes infections 50 flutamide 50 anterior uveitis 50 atheroma volume 50 anthracycline therapy 50 affective psychosis 50 IL6 50 mg calcium 50 cm2 50 Primary endpoints 50 oral prednisone 50 DOXIL 50 euthyroid 50 adult chronic ITP 50 advanced hepatocellular carcinoma 50 systolic blood pressures 50 Elevated CRP 50 virologic suppression 50 IU mL 50 CLINICAL STUDIES 50 postoperative AF 50 T1 hypointense lesions 50 plus prednisone 50 ritonavir boosted atazanavir 50 #mg q8h 50 erection hardness 50 refractory ischemia 50 vivo coagulation 50 Lenalidomide 50 κ 50 Secondary endpoints include 50 Leydig cell 50 fibrin deposition 50 allowance RDA 50 Crohn Disease Activity 50 #mV V 50 localized renal 50 Peginterferon alfa 2b 50 nadolol 50 Calcium intake 50 CaPre TM 50 Relapsed Refractory 50 beta blocker therapy 50 FOLFIRI 50 serum lipid levels 50 Pharmacokinetics PK 50 FluCAM arm 50 Lovaza ® 50 HBV DNA levels 50 alteplase 50 -#.# mm Hg 50 blood phenylalanine Phe 50 peginterferon 50 specific antigen PSA 50 glomerular 50 arteriolar 50 actions ordinaires accréditives Prix 50 % CI #.#-#.# [005] 50 plus ribavirin 50 definite stent thrombosis 49 urinary cadmium 49 LDL lowering 49 HLA DR4 immune 49 AUC0 #hr 49 glucose galactose malabsorption 49 tibolone 49 weekly subcutaneous injections 49 calcified plaques 49 binary restenosis 49 peginterferon alfa 2a #KD 49 oxyhemoglobin 49 EEG abnormalities 49 Papillary 49 CRp 49 urate oxidase 49 systolic diastolic 49 folic acid vitamin B# 49 K + ATPase 49 Â ± 49 mg dose 49 pharmacodynamics PD 49 pegfilgrastim 49 secretory phospholipase A2 49 #.#-#.# [011] 49 abdominal distension 49 Metformin HCl 49 genotypic resistance 49 DR5 49 reflux esophagitis 49 HGPIN 49 ACCORD Lipid 49 antidiabetic drug 49 placebo p = 49 modulate ion channel 49 achieved sustained virologic 49 severe oral mucositis 49 lopinavir 49 peginterferon alpha 2a 49 SHPT 49 neutrophil count 49 levalbuterol 49 peg interferon 49 decitabine 49 HCV genotype 1 49 null mice 49 intravenous bolus 49 mcg dose 49 mol L 49 imatinib therapy 49 cervical intraepithelial neoplasia 49 inhibitory concentrations 49 carotid plaque 49 hip BMD 49 COMBIVIR 49 androgen deprivation 49 argatroban 49 NNRTI resistance 49 FY#E EV EBITDA 49 antihypertensive agents 49 imipenem 49 Amino acid